Patents by Inventor Douglas Robert Cary

Douglas Robert Cary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL AMINO ACID DERIVATIVES
    Publication number: 20230257343
    Abstract: A novel amino acid derivative is provided, wherein the amino acid derivative is expected to improve solubility of polypeptides comprising the derivative therein.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 17, 2023
    Inventors: Naoki OKADA, Kyosuke UEDA, Masatoshi TAKUWA, Shunichi NAKANO, Kotaro TOKUMOTO, Tomoko ASHIZAWA, Shuhei YAMAKOSHI, Yutaka KOBAYASHI, Katsuma MATSUI, Ayumu MATSUDA, Masatoshi MATSUMOTO, Keiichi MASUYA, Atsushi YOSHIZAWA, Masahiko KINEBUCHI, Takeru EHARA, Masami YAMADA, Kouki MORIMOTO, Yoshihide MIZUKOSHI, Haruaki KURASAKI, Motoki MURAI, Kentarou FUKUMOTO, Douglas Robert CARY
  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • METHOD FOR PRODUCING PEPTIDE COMPOUND
    Publication number: 20220153777
    Abstract: The present invention is to provide a method for producing a peptide containing an N-alkylamino acid, which comprises the following Steps (1) to (3). Step (1): a step of mixing an N-terminal protected amino acid or an N-terminal protected peptide with a carboxylic acid halide or a halogenated alkyl formate; Step (2): a step of mixing an amino acid or a peptide in which the N-terminal and the C-terminal are not protected with a trialkylsilylating agent; and Step (3): a step of mixing the product obtained in Step (1) with the product obtained in Step (2).
    Type: Application
    Filed: March 16, 2020
    Publication date: May 19, 2022
    Applicants: NISSAN CHEMICAL CORPORATION, PeptiDream Inc.
    Inventors: Hisayuki TAKEUCHI, Yukio ASAKA, Akihiro NAGAYA, Michiharu HANDA, Keiichi MASUYA, Tomonori TAGURI, Yoshitaka NEMOTO, Yutaka KOBAYASHI, Ayumu MATSUDA, Haruaki KURASAKI, Douglas Robert CARY
  • HETEROCYCLIC COMPOUND
    Publication number: 20210363130
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 10696651
    Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 30, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jun Fujimoto, Xin Liu, Osamu Kurasawa, Terufumi Takagi, Douglas Robert Cary, Hiroshi Banno, Yasutomi Asano, Takuto Kojima
  • HETEROCYCLIC COMPOUND
    Publication number: 20190169166
    Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 6, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jun FUJIMOTO, Xin LIU, Osamu KURASAWA, Terufumi TAKAGI, Douglas Robert CARY, Hiroshi BANNO, Yasutomi ASANO, Takuto KOJIMA
  • Heterocyclic compound
    Patent number: 9957251
    Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 1, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Jun Fujimoto, Douglas Robert Cary, Masanori Okaniwa, Yasuhiro Hirata
  • Fused heterocyclic compound
    Patent number: 9745325
    Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 29, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masanori Okaniwa, Hiroshi Banno, Takaharu Hirayama, Douglas Robert Cary, Koji Ono, Naoki Iwamura
  • Cyclopropaneamine compound
    Patent number: 9682925
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 20, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara
  • HETEROCYCLIC COMPOUND
    Publication number: 20170044132
    Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu HIRAYAMA, Jun FUJIMOTO, Douglas Robert CARY, Masanori OKANIWA, Yasuhiro HIRATA
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20170037057
    Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 9, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masanori Okaniwa, Hiroshi BANNO, Takaharu HIRAYAMA, Douglas Robert CARY, Koji ONO, Naoki IWAMURA
  • CYCLOPROPANEAMINE COMPOUND
    Publication number: 20160130215
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 12, 2016
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara, Yusuke Tominari
  • Cyclopropaneamine compound
    Patent number: 9278931
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: March 8, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara, Yusuke Tominari
  • CYCLOPROPANEAMINE COMPOUND
    Publication number: 20140228405
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Application
    Filed: August 8, 2012
    Publication date: August 14, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara